Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs

Abstract

Background: Ancylostomatids ('hookworms') are among the most important zoonotic nematode parasites infecting dogs worldwide. Ancylostoma caninum and Uncinaria stenocephala are two of the most common hookworm species that infect dogs. Both immature and adult stages of hookworms are voracious blood feeders and can cause death in young dogs before infection can be detected by routine fecal examination. Hence, treatment of both immature and adult stages of hookworms will decrease the risk of important clinical disease in the dog as well as the environmental contamination caused by egg-laying adults, which should reduce the risk of infection for both dogs and humans. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ™), against induced larval (L 4), immature adult (L 5) and adult A. caninum, and adult U. stenocephala infections in dogs. Methods: Eight negative-controlled, masked, randomized laboratory studies were conducted. Two separate studies were conducted against each of the target parasites and stages. Sixteen or 18 purpose bred dogs, 8 or 9 in each of the two treatment groups, were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio ™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Timing of dosing relative to parasite inoculation allowed for efficacy to be evaluated primarily against the target parasite stage. Worm counts were conducted 7 or 8 days after treatments during necropsy. Efficacy was based on the number of worms recovered at necropsy compared to placebo control. Results: Based on geometric mean worm counts, efficacy of Simparica Trio ™ was ≥ 98.4% against L 4 larval stage of A. caninum, ≥ 99.8% against immature adult (L 5) A. caninum, and 100% against adult A. caninum and adult U. stenocephala. Conclusions: These studies confirm the efficacy of a single oral dose of a novel, chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio ™) against L 4 larval and immature adult (L 5) A. caninum, and adult A. caninum and U. stenocephala infections in dogs.

Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA

“…Simparica Trio ™ also demonstrated ≥ 98.3% efficacy against T. leonina, A. caninum and U. stenocephala in the European study, and 98.6% efficacy against A. caninum in the USA study. These results are in line with the efficacy of Simparica Trio ™ demonstrated against induced hookworm and roundworm infections in dogs [5,6]; thus, the present studies confirm that Simparica Trio ™ is also effective under field conditions in dogs of a variety of breeds, ages, and weight ranges, and in dogs most likely infected with varying numbers of ascarids and hookworms at differing developmental stages at the time of treatment.…”

“…A variety of approved medications are currently available for use in dogs [3,4]. A novel chewable oral tablet (Simparica Trio ™ , Zoetis, Parsippany, NJ, USA) containing sarolaner, moxidectin and pyrantel was recently shown in laboratory studies to be ≥ 95.2% effective against immature adult (L5) and adult T. canis, and ≥ 98.4% effective against L4 larval, immature adult (L5), and adult A. caninum in dogs with experimental infections [5,6]. Here we present two studies in which the safety and efficacy of Simparica Trio ™ was evaluated against naturally occurring gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA.…”

Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

“…The excellent efficacy against fleas and ticks observed in these studies, combined with efficacy for the prevention of heartworm and lungworm disease [29,30], and the treatment of roundworm and hookworm infections [31,32] in a single palatable tablet should make Simparica Trio ™ a convenient option for veterinarians and pet owners to routinely treat and control many of the common external and internal parasites of dogs.…”

Safety and efficacy of a novel oral chewable combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea infestations in client-owned dogs in the USA

“…This field study confirmed the safety and effectiveness of monthly dosing with Simparica Trio ™ for the treatment and prevention of fleas on dogs under normal home use conditions. This excellent flea control plus the added benefits of the combination providing coverage of the other major ecto-and endoparasites of dogs (ticks, heartworm, lungworm, gastrointestinal nematodes) in a single, palatable monthly dosage make this a convenient treatment option for veterinarians and dog owners [21][22][23][24][25].…”